Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Ambry's ExomeNext; PartnersHealthCare's VariantWire

Premium

Ambry Genetics has launched ExomeNext and ExomeNext-Rapid. The new assays feature faster turnaround times, reduced pricing, and more comprehensive coverage than Ambry's previous exome offering. ExomeNext has a list price of $5,800 with an eight to 12-week turnaround time, while ExomeNext-Rapid has a list price of $15,129 with a two to five-week turnaround time.


Partners HealthCare and GeneInsight have launched VariantWire, a clinical consortium offering clinical laboratories in the US and Canada the ability to share genetic testing data. VariantWire leverages a crowdsourcing mechanism to help laboratories interpret the significance of genetic variants. Founding members include: Partners HealthCare Laboratory for Molecular Medicine, ARUP Laboratories, and Mount Sinai Genetic Testing Laboratory at Icahn School of Medicine in New York. The Mount Sinai Hospital in Toronto and the Canadian Open Genetics Registry have also joined.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.